Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5080315 | 0.81 | ALDH1A1 (0.55) | F2RL3SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL4728430 | 0.80 | AMY1A (0.48) | F2RL3SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL11972713 | 0.78 | APP (0.54) | SMN1; SMN2MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL1977551 | 0.75 | MAPT (0.65) | SMN1; SMN2MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL4730485 | 0.74 | APP (0.66) | GAAGLAAPPCYP3A4 | |
| SCHEMBL4729268 | 0.74 | DYRK1A (0.56) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL1983245 | 0.72 | MEN1 (0.70) | SMN1; SMN2MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL8994212 | 0.72 | APP (0.48) | MEN1KMT2AALDH1A1MAPTTP53 | |
| SCHEMBL21794446 | 0.71 | MAPT (0.43) | SMN1; SMN2MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL2749006 | 0.71 | ALDH1A1 (0.58) | SMN1; SMN2MEN1KMT2AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0721336-B1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RES CAMPAIGN TECH (GB) | 1999-07-14 | — | — | EP | claimed |
| EP-0721336-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-17 | — | — | EP | claimed |
| WO-1995006469-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-03-09 | — | — | WO | claimed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0721336-B1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RES CAMPAIGN TECH (GB) | 1999-07-14 | — | — | EP | disclosed |
| US-5874431-A | ANTITUMOR AGENTS; BREAST CANCER | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-02-23 | — | — | US | disclosed |
| EP-0721336-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995006469-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | F2RL3 4556/4885SMN1; SMN2 11/4885MEN1 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.